ACM
IKT icon

Altium Capital Management’s Inhibikase Therapeutics IKT Stock Holding History

Altium Capital Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-18,292
Closed -$307K – 140
2021
Q2 		$307K Buy
+18,292
New +$538K 0.07% 127

Other funds holding IKT

ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Altium Capital Management's IKT Position: Q3 2021 in Review

Altium Capital Management sold out of Inhibikase Therapeutics (IKT) in Q3 2021, closing a stake of 18,292 shares — an estimated $307K sold.

Altium Capital Management first reported a position in IKT in Q2 2021 and held it in 1 quarter. The position peaked at $307K in Q2 2021. 21 funds tracked by Wall St. Rank hold IKT as of Q3 2021.

  • Altium Capital Management reported no remaining Inhibikase Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Altium Capital Management sold 18,292 Inhibikase Therapeutics shares in Q3 2021, an estimated $307K.
  • Altium Capital Management first reported a position in Inhibikase Therapeutics in Q2 2021 and held it in 1 quarter.
  • Altium Capital Management's Inhibikase Therapeutics position peaked at $307K in Q2 2021.
  • 21 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2021.

Based on Altium Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.